Johnson & Johnson (NYSE:JNJ) Stake Lessened by JGP Wealth Management LLC

JGP Wealth Management LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 68,230 shares of the company's stock after selling 10,548 shares during the period. JGP Wealth Management LLC's holdings in Johnson & Johnson were worth $9,867,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Summit Wealth Partners LLC raised its position in Johnson & Johnson by 0.6% in the second quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock valued at $1,463,000 after purchasing an additional 61 shares during the period. Powers Advisory Group LLC grew its stake in shares of Johnson & Johnson by 0.6% in the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock valued at $1,538,000 after buying an additional 61 shares in the last quarter. Eagle Wealth Strategies LLC raised its holdings in shares of Johnson & Johnson by 2.8% during the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock valued at $372,000 after buying an additional 63 shares during the period. Knuff & Co LLC boosted its holdings in Johnson & Johnson by 0.7% in the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock worth $1,534,000 after acquiring an additional 64 shares during the period. Finally, Perkins Coie Trust Co grew its position in Johnson & Johnson by 1.8% in the third quarter. Perkins Coie Trust Co now owns 3,705 shares of the company's stock valued at $600,000 after acquiring an additional 65 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on JNJ shares. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Bank of America dropped their target price on Johnson & Johnson from $166.00 to $160.00 and set a "neutral" rating on the stock in a research report on Friday. StockNews.com downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday. Royal Bank of Canada lifted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a report on Wednesday, October 16th. Finally, Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an "outperform" rating and a $190.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $174.29.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.74 during trading hours on Friday, reaching $147.03. The company's stock had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company's 50 day simple moving average is $148.51 and its 200 day simple moving average is $155.96. The stock has a market cap of $353.99 billion, a P/E ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business's revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.66 earnings per share. As a group, analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.